Invitrogen™ TRAIL-R2 (DR5) Polyclonal Antibody

Description

A suggested positive control is Hela cell lysate. PA5-19895 can be used with blocking peptide PEP-0021. The PA5-19895 immunogen is located within the last 50 amino acids of DR5. Predicted molecular ~ 48kD and 45kD. In Western blot applications, this antibody has been observed to detect a band at: 48kD and 45kD.

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.